» Articles » PMID: 21062218

Antithrombin Deficiency and Its Laboratory Diagnosis

Overview
Specialties Biochemistry
Pathology
Date 2010 Nov 11
PMID 21062218
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Antithrombin (AT) belongs to the serpin family and is a key regulator of the coagulation system. AT inhibits active clotting factors, particularly thrombin and factor Xa; its absence is incompatible with life. This review gives an overview of the protein and gene structure of AT, and attempts to explain how glucosaminoglycans, such as heparin and heparan sulfate accelerate the inhibitory reaction that is accompanied by drastic conformational change. Hypotheses on the regulation of blood coagulation by AT in physiological conditions are discussed. Epidemiology of inherited thrombophilia caused by AT deficiency and its molecular genetic background with genotype-phenotype correlations are summarized. The importance of the classification of AT deficiencies and the phenotypic differences of various subtypes are emphasized. The causes of acquired AT deficiency are also included in the review. Particular attention is devoted to the laboratory diagnosis of AT deficiency. The assay principles of functional first line laboratory tests and tests required for classification are discussed critically, and test results expected in various AT deficiency subtypes are summarized. The reader is provided with a clinically oriented algorithm for the correct diagnosis and classification of AT deficiency, which could be useful in the practice of routine diagnosis of thrombophilia.

Citing Articles

Molecular Mechanisms of the Impaired Heparin Pentasaccharide Interactions in 10 Antithrombin Heparin Binding Site Mutants Revealed by Enhanced Sampling Molecular Dynamics.

Balogh G, Bereczky Z Biomolecules. 2024; 14(6).

PMID: 38927061 PMC: 11201378. DOI: 10.3390/biom14060657.


Clinical and Molecular Characterization of Nine Novel Antithrombin Mutations.

Kallai J, Gindele R, Penzes-Daku K, Balogh G, Bogati R, Becsi B Int J Mol Sci. 2024; 25(5).

PMID: 38474138 PMC: 10931778. DOI: 10.3390/ijms25052893.


Antithrombin Therapy: Current State and Future Outlook.

Rodgers G, Mahajerin A Clin Appl Thromb Hemost. 2023; 29:10760296231205279.

PMID: 37822179 PMC: 10571690. DOI: 10.1177/10760296231205279.


Comparison of antithrombin activity assays in detection of patients with heparin binding site antithrombin deficiency: systematic review and meta-analysis.

Rojnik T, Sedlar N, Turk N, Kastrin A, Debeljak M, Bozic Mijovski M Sci Rep. 2023; 13(1):16734.

PMID: 37794095 PMC: 10551003. DOI: 10.1038/s41598-023-43941-x.


Identification and characterization of two SERPINC1 mutations causing congenital antithrombin deficiency.

Wang H, Ruan D, Wu M, Ji Y, Hu X, Wu Q Thromb J. 2023; 21(1):3.

PMID: 36624481 PMC: 9830717. DOI: 10.1186/s12959-022-00443-6.